Eli Lilly and Company (NYSE:LLY) Shares Sold by Symphony Financial Ltd. Co.

Symphony Financial Ltd. Co. trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 9.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,182 shares of the company’s stock after selling 419 shares during the quarter. Symphony Financial Ltd. Co.’s holdings in Eli Lilly and Company were worth $1,941,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Banco Bilbao Vizcaya Argentaria S.A. grew its position in Eli Lilly and Company by 4.8% during the first quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 82,966 shares of the company’s stock valued at $28,449,000 after acquiring an additional 3,768 shares during the period. Thrive Wealth Management LLC increased its position in Eli Lilly and Company by 103.7% during the 2nd quarter. Thrive Wealth Management LLC now owns 1,522 shares of the company’s stock worth $714,000 after purchasing an additional 775 shares in the last quarter. L2 Asset Management LLC increased its position in Eli Lilly and Company by 4.5% during the 1st quarter. L2 Asset Management LLC now owns 2,014 shares of the company’s stock worth $692,000 after purchasing an additional 86 shares in the last quarter. Patten & Patten Inc. TN raised its holdings in Eli Lilly and Company by 44.2% in the first quarter. Patten & Patten Inc. TN now owns 17,177 shares of the company’s stock valued at $5,899,000 after buying an additional 5,266 shares during the period. Finally, Missouri Trust & Investment Co lifted its position in Eli Lilly and Company by 3.2% during the first quarter. Missouri Trust & Investment Co now owns 774 shares of the company’s stock valued at $266,000 after buying an additional 24 shares in the last quarter. 81.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. HSBC started coverage on shares of Eli Lilly and Company in a research note on Friday, July 14th. They issued a “buy” rating and a $560.00 target price on the stock. Royal Bank of Canada boosted their price objective on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. Citigroup increased their target price on Eli Lilly and Company from $360.00 to $525.00 and gave the company a “buy” rating in a research note on Wednesday, July 26th. Argus boosted their price target on Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. Finally, BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twenty have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $532.78.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $2.33 during trading hours on Tuesday, reaching $573.61. The stock had a trading volume of 1,000,334 shares, compared to its average volume of 3,025,117. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87. The firm has a 50-day simple moving average of $512.56 and a 200-day simple moving average of $439.28. The firm has a market capitalization of $544.52 billion, a PE ratio of 80.02, a price-to-earnings-growth ratio of 2.37 and a beta of 0.32. Eli Lilly and Company has a twelve month low of $296.32 and a twelve month high of $601.84.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The business had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. During the same period in the previous year, the firm posted $1.25 earnings per share. The business’s revenue was up 28.1% on a year-over-year basis. As a group, equities analysts forecast that Eli Lilly and Company will post 9.84 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend was Monday, August 14th. Eli Lilly and Company’s payout ratio is currently 62.87%.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $571.41, for a total transaction of $119,996,100.00. Following the sale, the insider now directly owns 99,983,810 shares in the company, valued at approximately $57,131,748,872.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the transaction, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $571.41, for a total transaction of $119,996,100.00. Following the completion of the sale, the insider now directly owns 99,983,810 shares of the company’s stock, valued at $57,131,748,872.10. The disclosure for this sale can be found here. Insiders sold 976,153 shares of company stock valued at $21,080,192,113 over the last 90 days. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.